Live feed07:00:00·26dPRReleaseOpen Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)BMY· Bristol-Myers Squibb CompanyHealth CareOriginal source
